Raising high-density lipoprotein

[1] Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) : 220 - 228

[2] Plasma lipids and cardiovascular risk: a POSCH report [J]. ATHEROSCLEROSIS, 2001, 154 (01) : 221 - 227

[3] CANNER PL, 2002, CIRCULATION S2, V106, P3138

[4] CANNY JF, 1986, PAMI, V8, P6, DOI DOI 10.1109/TPAMI.1986.4767851

[5] Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (03) : 490 - 497

[6] Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease - The ADMIT Study: A randomized trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (10): : 1263 - 1270

[7] FEHER MD, 2003, LIPIDS LIPID DISORDE

[8] NICOTINIC-ACID AS THERAPY FOR DYSLIPIDEMIA IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (06): : 723 - 726

[9] Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes - Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (14) : 1568 - 1576

[10] MCGOVERN ME, 2004, BR J DIABETES VASC D, V4, P78, DOI DOI 10.1177/14746514040040020301

[1] Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) : 220 - 228

[2] Plasma lipids and cardiovascular risk: a POSCH report [J]. ATHEROSCLEROSIS, 2001, 154 (01) : 221 - 227

[3] CANNER PL, 2002, CIRCULATION S2, V106, P3138

[4] CANNY JF, 1986, PAMI, V8, P6, DOI DOI 10.1109/TPAMI.1986.4767851

[5] Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (03) : 490 - 497

[6] Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease - The ADMIT Study: A randomized trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (10): : 1263 - 1270

[7] FEHER MD, 2003, LIPIDS LIPID DISORDE

[8] NICOTINIC-ACID AS THERAPY FOR DYSLIPIDEMIA IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (06): : 723 - 726

[9] Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes - Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (14) : 1568 - 1576

[10] MCGOVERN ME, 2004, BR J DIABETES VASC D, V4, P78, DOI DOI 10.1177/14746514040040020301